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REPRODUCTIVE HEALTH CONCERNS FOR
WOMEN WITH EPILEPSY
Snjeæana Mi¹kov
University Department of Neurology, Sestre milosrdnice University Hospital, Zagreb, Croatia
SUMMARY · Pregnancy has some important implications for women with epilepsy. Appropriate
counseling and support for women with epilepsy who are pregnant or contemplating pregnancy have
raised a number of issues about their proper treatment. The impact of epilepsy on fertility and preg-
nancy must be carefully managed. This includes the effect of pregnancy on seizure frequency, the
effect of seizures on the fetus, birth defects and possible teratogenic effect of antiepileptic drugs,
complications of pregnancy, the implications for breast feeding, and precautions for the mothers having
seizures when taking care of their newborn and young children. Understanding of the risk associated
with epilepsy in pregnancy, use of appropriate therapy, and close teamwork of the neurologist, obste-
trician, pediatrician and the woman herself will help ensure a safe pregnancy and delivery outcome.
The knowledge and awareness of these issues are of great importance for optimal care of these women.
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Introduction
Epilepsy is a very common and serious neurologic
condition, with a 10-fold prevalence of multiple sclero-
sis and 100-fold that of motor neuron disease. The in-
cidence of epilepsy (annual rate of occurrence of new
cases) is a measure of the number of cases per 100,000
inhabitants per year. It ranges between 40 and 70 per
100,000 in most developed countries, and between 100
and 190 per 100,000 in developing countries. This makes
epilepsy the third most common neurologic disorder,
immediately following stroke and Alzheimer’s disease.
Epilepsy is an episodic and paroxysmal condition. It is
a frightening condition, misunderstood by many, includ-
ing health care professionals. This has placed an extra
burden on patients with epilepsy who often face dis-
crimination in everyday life1,2. Despite the fact that
about 50% of patients with epilepsy are women, it is only
during the last two decades that the interest in special
issues concerning epilepsy in women has risen and has
been systematically studied3.
Fertility and Reproductive Dysfunction
Men and women with epilepsy are at a risk of repro-
ductive dysfunction. Birth rates equal only one third to
two thirds of those among persons without epilepsy. For
women with epilepsy, infertility has been attributed to
menstrual irregularity, pituitary hormone abnormalities,
anovulatory cycles, and polycystic ovaries. Both men and
women experience disturbances and disorders of sexual
desire and arousal, which may affect even 40% of persons
with epilepsy. Reproductive dysfunction is common in
women with epilepsy3,4.
The prevalence of menstrual cycle disruption, anovu-
latory cycles, disturbances of hypothalamic hormones,
pituitary hormones, or both, and disturbances of gonadal
steroids is increased in women with epilepsy. The mecha-
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nism of reproductive dysfunction is not fully understood.
Reproductive dysfunction may be due to psychologic,
pharmacologic, or physiologic factors. However, epilepsy
related brain dysfunction in the regions mediating repro-
ductive physiology and behavior is likely to be partly re-
sponsible for this phenomenon. In addition, antiepileptic
drugs (AEDs) contribute to reproductive health disorders
by decreasing plasma steroid levels (carbamazepine,
phenytoin, phenobarbital), or by increasing plasma levels
of gonadal androgens (valproate)5,6.
Polycystic ovaries and menstrual cycle irregularities are
more common in women receiving valproate, probably
related to valproate association with weight gain and
hyperinsulinemia3,5,6.
Birth Control
Counseling about contraception is important for two
reasons. First, the enzymes inducing AEDs (carbama-
zepine, oxcarbazepine, phenytoin, phenobarbital, pri-
midone, and topiramate) lower the efficacy of oral con-
traception by increasing steroid hormone-binding globu-
lin with reduction of free hormone levels. This leads to the
reduction of exogenous estradiol and progesterone levels
in women using hormonal contraception,  and to failure
of hormonal contraception. A combination of oral con-
traceptives with an estrogen content higher than normally
recommended is therefore advisable. Birth control drugs
containing at least 50 mg of estradiol or mestranol are
recommended. Enzyme induction does not seem to be a
problem with valproic acid, lamotrigine, felbamate,
gabapentine, tiagabine or zonisamide.
About 10% of women with epilepsy experience a peak
in seizure frequency around the time of menstruation
(catamenial epilepsy), some patients also experience such
an increase at ovulation. The possible explanation may be
related to hormonal changes, however, despite several at-
tempts to find an efficacious treatment for these problems,
only a limited success has been achieved1,5.
Pregnancy and Childbirth
Seizure frequency during pregnancy
Epilepsy is the most commonly encountered neurologic
disorder during pregnancy. About one third of women with
epilepsy experience an increased frequency of seizures dur-
ing pregnancy. Seizure exacerbation usually occur at the end
of the first and at the beginning of the second trimester,
mainly as the result of a variety of physiologic changes and
noncompliance. Some women have seizures only during
pregnancy. The likelihood of change in the seizure fre-
quency appears to be independent of seizure type and their
pregestational frequency. Seizures may occur de novo in
pregnancy as the result of idiopathic epilepsy, occurring in
pregnancy for the first time (gestational epilepsy). Seizures
may also occur following cerebrovascular disease, eclamp-
sia, hyponatremia caused by water retention from oxytoin,
i.v. lidocaine during epidural anesthesia, syncope with sei-
zures, or as psychogenic seizures8-11.
Pharmacological Changes
Pregnancy is associated with a number of physiologic,
endocrine and psychological changes, any or all of which
might contribute to lowering the seizure threshold. A ma-
jor factor is poor compliance in taking antiepileptic medi-
cation because of the fear concerning malformations in the
offspring. Psychological stress factors such as anxiety lead-
ing to the lack of sleep have been postulated as important
in lowering the seizure threshold. Although some preg-
nant women have an exacerbation of their seizures because
of noncompliance or sleep deprivation, in the majority of
these women a number of physiologic changes are respon-
sible for the increase in seizure frequency. Women often
gain weight during pregnancy, which may be partly caused
by the increased retention of water and sodium. An in-
crease of the volume into which the drug is distributed
may result in lower plasma concentrations, even if the rate
of drug metabolism or renal excretion is not altered. Lower
plasma concentrations of AEDs during pregnancy, there-
fore, appear to be related to the combined effect of en-
hanced hepatic metabolism and an increased volume of
distribution. The greatest change in plasma levels occur
during the first trimester with phenobarbital and pheny-
toin, and during the third trimester with carbamazepine.
During gestation, changes occur in protein binding of
AEDs. Plasma albumin concentrations tend to decline
during pregnancy, which leads to a proportional reduction
in protein binding of drugs. The free (non-protein bound)
levels of the drug may even increase, so the free drug con-
centration, which is the pharmacologically active portion,
may change very little. That is why it is sometimes nec-
essary to monitor the effective drug concentrations, mea-
suring the concentrations of free drug, especially in case
of phenytoin and valproate. After pregnancy, the pharma-
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cokinetic values of the drug usually return to the prege-
stational values within 8 weeks1,12-15.
Unfavorable pregnancy and fetal outcomes are more
likely to occur in women with epilepsy. The developing
fetus in epileptic patients is exposed to two risk sources:
metabolic and mechanical stresses from generalized tonic-
clonic seizures, and problems caused by antiepileptic
medication and their metabolites. A balanced risk from
medication against the risk from increased seizures re-
quires the exercise of careful judgment based on the most
current information1,12,13,16.
Teratogenicity of AEDs
Antiepileptic drugs are associated with an increased
risk of birth defect. The risk of both major fetal malfor-
mations and minor anomalies is increased in epileptic
women taking AEDs, probably because of the complex
inter-relationship among undefined genetic factors related
to epilepsy itself, the AEDs used, and major seizures oc-
curring during pregnancy. The overall risk of having a
baby with some major malformation is about 2% to 3%
in healthy population, and is increased in women with
epilepsy. Although AEDs increase the risk of congenital
anomalies, the risk of malformations is increased in moth-
ers with epilepsy regardless of whether or not they are
taking AEDs. The risk is even higher if the mother is on
AED. Interestingly enough, the incidence of malforma-
tions was highest (12.7%) in medicated patients who had
seizures during pregnancy. Thus, the highest risks of fe-
tal injury occur in women whose seizures are incompletely
controlled with multiple drug use1,3,12,13.
The risk of malformation in any individual pregnancy
in women with epilepsy on antiepileptic monotherapy is
estimated to be between 4% and 6%. In other words,
women with epilepsy on monotherapy have a nearly 95%
chance of having a healthy baby. The risk is increased, per-
haps even doubled, by use of two or more drugs, and also
by very high plasma levels of AEDs. All of the AEDs have
been associated with congenital malformations, although
the incidence and type of malformations may vary with the
drugs used. The major malformations encountered most
often are cardiac and ‘midline’ defects (cleft lip/palate),
however, others involving the brain and spine may also
occur. Current evidence suggest that, with the exception of
trimethadione and valproate, all current AEDs from the
older group of AEDs carry similar risks of malformation.
Trimethadione, which should never be used in pregnancy,
results in major malformations or fetal loss in 87% of preg-
nancies. Valproate, both as monotherapy and in polythe-
rapy, has been associated with a 1% to 2% risk of neural tube
defects. The risk of spina bifida appears to be significantly
higher in infants exposed not only to valproate but also to
carbamazepine (approximately 0.5% to 1%). Infants born
to mothers on AEDs are at an increased risk of minor
anomalies (prominent lips, fingernail hypoplasia, hyper-
telorism, etc.). The risk of spina bifida is increased with a
family history of a prior child with spina bifida, folate de-
ficiency, high diurnal fluctuations in blood levels of AEDs,
and polytherapy. Primidone appears to be more teratoge-
nic than phenobarbital itself. However, the claims that bar-
biturates are less teratogenic than other AEDs, with the
exception of trimethadione, cannot be substantiated by the
available literature data10,14,17.
While some of the increased risk is attributable to
AEDs, the more likely cause is the complex interaction
of genetic factors and environmental factors (drugs, vi-
tamin deficiencies, etc.) working in connection. Little
data are available on the teratogenicity of newer AEDs
in humans. However, animal studies in equivalent spe-
cies have shown that gabapentine, lamotrigine, topi-
ramate, tiagabine, vigabatrine and felbamate do not have
significant teratogenicity, but limited experience in pa-
tients prevents giving any definite statement about their
safety9,18-20.
There appears to be a strong association between ma-
ternal folic acid deficiency and fetal malformation, spon-
taneous abortion and placental abruption2,14.
Labor and Delivery
Hemorrhagic disease of the newborn can occur due to
the induction of vitamin K metabolism by inducing AEDs
and deficiency of vitamin K-dependent clotting factors. It
tends to occur in the first 24 hours postpartum, involves
abdominal hemorrhages, and is associated with a 30%
mortality. The mechanism underlying this deficit is thought
to be the induction of hepatic enzymes by AEDs. Vitamin
D levels may often be below normal. The prevalence of
complications of labor and delivery, such as preeclampsia,
vaginal bleeding, placenta previa, abruptio placentae,
polyhydramnion, assisted delivery, cesarean section, prema-
turity and intrauterine growth retardation, may be slightly
increased in women with epilepsy. An increase in perinatal
mortality (stillbirth or death in the first week postpartum)
is most consistently reported.
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The fetus is protected from the physiologic effect of
maternal seizures, but miscarriages can occur with pro-
longed seizures or status epilepticus. The factors involved
in these unfavorable outcomes may be socioeconomic or
genetic, and may be related to seizures or AEDs.
Only 1.2% of the women with epilepsy will experience
seizures during labor or in the first 24 hours after deliv-
ery. As in all mothers, breast feeding is encouraged. Most
AEDs are extracted in the milk but it seldom causes prob-
lems. The benefits of breast feeding (reduced risk of in-
fections) must be weighted against the immediate and
long-term risk of exposure of the infant to AEDs.
Management for Epilepsy in Pregnancy
A decision on AED therapy should be made before
the woman becomes pregnant. The issue must be dis-
cussed with all epileptic women of childbearing poten-
tial. The woman and her partner have the responsibility
to decide whether or not to bear the children. The role
of physician should focus on providing information on
the risks of childbearing and on providing medical care
to reduce the risks as much as possible before the patients
become pregnant. The most critical step in caring for an
epileptic woman of childbearing age is to properly di-
agnose the syndrome. Consideration must be given to
whether AEDs are needed. Has the woman been sei-
zure-free for 2 to 5 years, the need to continue drug
therapy should be reconsidered. If the woman receives
polytherapy, regimen simplification and dose optimiza-
tion should be considered before pregnancy. Mo-
notherapy should be reduced to the lowest effective dose.
Generally, AEDs that are effective and well tolerated
should not be changed. Initial selection of drugs with the
least teratogenic potentials, such as carbamazepine,
clobazam, or possibly some of the newer drugs such as
gabapentine, lamotrigine, topiramate, tiagabine, viga-
batrine, is recommended in women who wish to be preg-
nant. However, the women with a family history of spina
bifida should probably avoid valproic acid and carbama-
zepine. During pregnancy, toxic and subtherapeutic con-
centrations should be avoided. Blood levels of AED (es-
pecially free drug levels) must be monitored. Dose ad-
justments may be necessary if significant declines occur.
The necessity of good compliance should be constantly
reinforced1,3,7,9,11.
Folate, 0.5-1.0 mg per day, should be given to women
with childbearing potential who are on AEDs. The doses
could be increased to 5 mg per day in patients trying to
conceive20.
Fetal high-resolution ultrasonography should be per-
formed to rule out spina bifida, cardiac anomalies, or limb
defects at the gestational age of 16 to 18 weeks. If ultra-
sound raises suspicion of spina bifida, amniocentesis
should be performed, and alfa-fetoprotein levels should
be obtained3,21.
Proper nutrition and adequate sleep are essential. The
patients should avoid the use of any other medication
except for that prescribed by the physician. Cigarette
smoking and alcohol consumption should be avoided,
because they have been associated with fetal anomalies18.
To prevent hemorrhagic disease of the newborn (pos-
sibly due to the induction of enzymes degrading vitamin
K), vitamin K oral supplementation at a dose of 20 mg per
day should be administered for 4 weeks prepartum6,10.
Breast feeding is generally safe. Epileptic women tak-
ing anticonvulsant drugs who want to nurse should not
be discouraged. Unless the mother is taking barbiturates,
which may sedate babies, there are not many reasons to
prevent breast feeding, even though small quantities of
AEDs will appear in the breast milk. A fetus exposed
prepartum to barbiturates may have withdrawal symptoms
after the first week postpartum. Mothers with seizures are
able to take care of their infants, but they must think of
precautions when taking care of them and performing
some tasks9,10,21.
Conclusion
Preconception counseling is arguably the most impor-
tant information a woman with epilepsy receives. The
most important aspect for a woman with epilepsy is main-
taining an open dialogue between the physician and the
patient. There is a consensus today that more than 90%
of women with epilepsy who receive AED therapy will
deliver normal children. Compared to women in the gen-
eral population, the risk for infants of developing malfor-
mations if having an epileptic mother is significantly
higher. The risk of malformation in any individual preg-
nancy in a woman with epilepsy on single AED is esti-
mated to range between 4% and 6%. The risk of a major
malformation development is also increased in mothers
on polytherapy or in those receiving toxic levels of AEDs.
To ensure the best outcome, only those women with an
established diagnosis of epilepsy should receive medica-
tion. Understanding the risks associated with epilepsy in
Mi¹kov S. Reproduction and epilepsy
Acta clin Croat, Vol. 41, No. 1, 2002 55
pregnancy, use of appropriate therapy, and close teamwork
among the neurologist, obstetrician, pediatrician and the
woman herself will help ensure an uneventful pregnancy
and delivery for most epileptic women.
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Saæetak
REPRODUKCIJSKI ZDRAVSTVENI PROBLEMI U ÆENA S EPILEPSIJOM
S. Mi¹kov
Za æene koje boluju od epilepsije trudnoÊa ima veliko znaËenje. Potreba za prikladnim savjetovanjem i potporom u ovih
bolesnica potakla je brojna istraæivanja. U lijeËenju ovih bolesnica treba uzeti u obzir utjecaj epilepsije na fertilitet i trudnoÊu.
Osobito je vaæno obratiti pozornost na utjecaj trudnoÊe na uËestalost epileptiËnih napadaja, utjecaj napadaja na fetus, moguÊu
teratogenost antiepileptiËnih lijekova, njihov utjecaj na dojenje, utjecaj napadaja na sposobnost majke da se brine o svom
novoroðenËetu i malom djetetu. Sigurniji ishod trudnoÊe i poroðaja moæe se osigurati razumijevanjem rizika povezanog s
epilepsijom u trudnoÊi, uporabom prikladne specifiËne antiepileptiËne terapije, kao i timskom suradnjom izmeðu neurologa,
ginekologa, pedijatra i same trudnice koja boluje od epilepsije.
KljuËne rijeËi: TrudnoÊa, komplikacije; TrudnoÊa, prevencija i kontrola; Epilepsija, medikamentna terapija; Zdravlje u æena
